Retroperitoneal sarcomas exhibit >20% lower 5-year survival than limb tumors, higher distant metastasis rates, and unique biological behaviors (e.g., VEGF overexpression, hypervascularity) potentially driving aggressive progression. Here, VEGFA is linked to retroperitoneal sarcoma.